<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03944044</url>
  </required_header>
  <id_info>
    <org_study_id>17-245</org_study_id>
    <nct_id>NCT03944044</nct_id>
  </id_info>
  <brief_title>Paracetamol Route in Palliative Care Patients (PARASCIVPALLIA)</brief_title>
  <acronym>PARASCIVPALL</acronym>
  <official_title>Paracetamol Route in Palliative Care Patients : Intravenous Versus Subcutaneous Route Pharmacokinetics, Study Protocol for a Randomized Equivalence Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Among palliative-care patients, subcutaneous route is often an alternative to&#xD;
      intravenous route yet pharmacological and clinical data are lacking. Many French palliative&#xD;
      crew are now using empirically paracetamol by subcutaneous route also there is no data to&#xD;
      support this practice. The aim of the present study is to compare pharmacokinetics parameters&#xD;
      between intravenous and subcutaneous route for palliative-care patients.&#xD;
&#xD;
      Methods/design: A randomized, open, crossover, bicenter study in two palliative care centers.&#xD;
      The aim is to demonstrate the pharmacokinetic equivalence between the two routes of&#xD;
      administration. Data analysis will be performed by Wilcoxn's signed Rank Test with an alpha&#xD;
      risk of 5 percent. All adverse events will be reported for a safety analysis.&#xD;
&#xD;
      Discussion: This trial may permit, if a pharmacokinetic equivalence is established, to build&#xD;
      randomized controlled trials to then assess the efficacy and tolerability of subcutaneous&#xD;
      paracetamol administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">June 15, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>This is a comparative, randomized, open, crossover, bicenter clinical trial with SC and IV paracetamol injections successively given to each patient.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>At injection time</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>15 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>60 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>90 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>120 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>240 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>360 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after intravenous route</measure>
    <time_frame>480 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after intravenous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>at injection time</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>15 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>30 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>45 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>60 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>90 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>120 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>240 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>360 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <primary_outcome>
    <measure>paracetamolemia dosage after subcutaneous route</measure>
    <time_frame>480 minutes after injection</time_frame>
    <description>measurement of paracetamol blood concentration after subcutaneous route</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>at injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>15 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>60 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>90 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>120 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>240 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>360 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pain scale</measure>
    <time_frame>480 minutes after injection time</time_frame>
    <description>numeric sale (0-10)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Palliative Care</condition>
  <arm_group>
    <arm_group_label>Subcutaneous route first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The first route of administration is designated by randomization. In the subcutaneous group, patients received intravenous route in a second time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous route first</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The first route of administration is designated by randomization. In the intravenous group, patients received subcutaneous route in a second time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Paracetamol route in palliative-care patients: intravenous versus subcutaneous route Pharmacokinetics study protocol</intervention_name>
    <description>Compare the pharmacokinetic (PK) of SC and intravenous (IV) routes in the same patient in a palliative care situation, to determine if there is a PK equivalence between these two modes of administration of Paracetamol.</description>
    <arm_group_label>Intravenous route first</arm_group_label>
    <arm_group_label>Subcutaneous route first</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old, hospitalized&#xD;
&#xD;
          -  Patients in a palliative care situation&#xD;
&#xD;
          -  Patients having an intravenous device with the presence of a venous reflux (be&#xD;
             implantable venous site, picc-line, central track)&#xD;
&#xD;
          -  Patients having a spontaneous pain, not related to care, with a numeric pain rate&#xD;
             scale (NPRS) &gt; 3/10 or have a systematic prescription of paracetamol in the usual&#xD;
             treatment&#xD;
&#xD;
          -  Patients able to do an auto-evaluation of their pain by NPRS&#xD;
&#xD;
          -  No contraindications of paracetamol&#xD;
&#xD;
          -  No contraindications of alternative antalgic (low opioids, strong opioids,&#xD;
             Non-steroidal anti-inflammatory)&#xD;
&#xD;
          -  Possibility to not take paracetamol in the previous 24 hours before inclusion&#xD;
&#xD;
          -  Patients with a blood test dating back less than 7 days, with no severe renal or&#xD;
             hepatic failure&#xD;
&#xD;
          -  Patients related with a French social security regime&#xD;
&#xD;
          -  Patients accept to participate in the study, with written consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under legal protection&#xD;
&#xD;
          -  Patients who participate in another study less than 30 days before&#xD;
&#xD;
          -  Patients weighing less than 50 kg&#xD;
&#xD;
          -  Patients having a contraindication to subcutaneous route&#xD;
&#xD;
          -  Pregnant or breastfeeding woman&#xD;
&#xD;
          -  Patients who having a paracetamol administration less than 24 hours before the&#xD;
             beginning of the inclusion&#xD;
&#xD;
          -  Patients who having a low opioid less than 2 hours before or a strong opioid less than&#xD;
             one hour before the beginning of administration of paracetamol&#xD;
&#xD;
          -  Patients having a fever&#xD;
&#xD;
          -  No possibility of communication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>January 25, 2019</study_first_submitted>
  <study_first_submitted_qc>May 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2019</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paracetamol</keyword>
  <keyword>Acetaminophen</keyword>
  <keyword>Palliative care</keyword>
  <keyword>Subcutaneous administration</keyword>
  <keyword>intravenous administration</keyword>
  <keyword>pharmacokinetic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

